Findings from a new study led by Yale Cancer Center show the small molecule inhibitor drug, PF05175157, originally developed to treat diabetes by Pfizer, may help in the treatment of breast cancer. The findings were reported today at the 2021 San Antonio Breast Cancer Symposium in San Antonio, Texas.
New research led by Yale Cancer Center reveals young women with breast cancer and a family history of the disease, but no high penetrance germline mutations, have an increased number of rare germline variants in cancer-relevant genes.
In recognition of Pancreatic Cancer Awareness Month in November, Yale Cancer Center early detection research is providing new reason for optimism.
Several Yale Cancer Center faculty have authored chapters in a newly released book, A New Deal For Cancer: Lessons from a 50 Year War.
In a large study led by Yale Cancer Center, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening. The results also showed significant increases in PSA testing among older men, a group for whom screening is not routinely recommended.
New findings by researchers at Yale Cancer Center demonstrate a novel strategy to treat tumor growth in breast and ovarian cancers characterized by HER2 gene amplification, an increase in the number of copies of a gene.
20221027104337.jpg&width=400&height=400)
The National Institutes of Health has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center.
A new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity.
Yale Cancer Center and Smilow Cancer Hospital experts explain why the PALB2 gene can increase your breast cancer risk.
Women Leaders in Oncology (WLO) has named Pamela Kunz, MD, the 2021 Woman Oncologist of the Year. Kunz is Associate Professor of Medicine (Medical Oncology), Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, Chief of GI Medical Oncology and Vice Chief, Diversity Equity and Inclusion, Medical Oncology.
The National Cancer Institute has recognized Markus Müschen, MD, PhD, with its Outstanding Investigator Award.
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer.
New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer.
In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.
A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The goal of the study is to provide views on how basic science advances will impact clinical research areas to help influence how NSCLC will be managed over the coming decade.
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier (BBB) and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.
A study led by researchers at Yale Cancer Center, Stony Brook University and KDx Diagnostics, Inc., examined a revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker, and revealed the test can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.
In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income. The results were published online today in the Journal of Clinical Oncology (JCO).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
